Holen Sie sich die Stockscreener-App
1.78
5.33%
0.09
Schlusskurs vom Vortag:
$1.69
Offen:
$1.71
24-Stunden-Volumen:
5,121
Relative Volume:
0.53
Marktkapitalisierung:
$55.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-0.7064
EPS:
-2.5197
Netto-Cashflow:
-
1W Leistung:
+7.23%
1M Leistung:
+22.76%
6M Leistung:
-21.24%
1J Leistung:
-37.18%
1-Tages-Spanne:
$1.70
$1.845
1-Wochen-Bereich:
$1.62
$1.845
52-Wochen-Spanne:
$1.10
$3.89
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Firmenname
Adlai Nortye Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ANL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
1.78 | 62.36M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Aktie (ANL) Neueste Nachrichten
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 News Drivers & AI Powered Market Entry Ideas - Newser
Live market analysis of SPAIJuly 2025 Intraday Action & AI Forecasted Entry and Exit Points - Newser
Key resistance and support levels for Adlai Nortye Ltd. Depositary ReceiptJuly 2025 Final Week & Fast Gain Stock Tips - Newser
Candlestick signals on FBGL stock todayForecast Cut & Stock Market Timing Techniques - Newser
F.N.B. Corporation stock trendline breakdownJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - Newser
Is Brookfield Asset Management Ltd. stock reversal real or fake2025 Price Action Summary & Reliable Price Breakout Alerts - Newser
How to use a screener to detect IROHW breakouts2025 Risk Factors & Expert Curated Trade Setups - Newser
Analyzing drawdowns of Coeptis Therapeutics Holdings Inc. with statistical toolsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Is GSK plc ADRhedged forming a bottoming base2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Trend analysis for Intercontinental Exchange Inc. this weekWeekly Risk Report & Reliable Intraday Trade Alerts - Newser
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Long term hold vs stop loss in CEADJuly 2025 PostEarnings & Reliable Price Breakout Alerts - Newser
Adlai Nortye (NASDAQ:ANL) Stock Price Up 3.2% – Should You Buy? - Defense World
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
AlphaTime Acquisition Corp Debt Equity Composite Units recovery potential after sell offFree Long Hold Safe Return Strategy - Newser
Comparing Adlai Nortye Ltd. Depositary Receipt in custom built stock radarsDaily Upside Movement Prediction With Data - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Adlai Nortye Ltd. Announces 2025 Share Incentive Plan and Board Changes - TipRanks
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Adlai Nortye (NASDAQ:ANL) Trading Down 5.5% – Here’s What Happened - Defense World
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS By Investing.com - Investing.com South Africa
H.C. WAINWRIGHT CUTS ADLAI NORTYE STOCK RATING AFTER TRIAL RESULTS - Investing.com
Adlai Nortye Discontinues Buparlisib Development After Phase III Trial Results - TipRanks
ANL stock touches 52-week low at $1.71 amid sharp annual decline - Investing.com India
ANL stock touches 52-week low at $1.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Adlai Nortye to present at AACR Annual Meeting with two abstracts scheduled. - AInvest
ANL stock touches 52-week low at $1.85 amid sharp annual decline By Investing.com - Investing.com South Africa
ANL stock touches 52-week low at $1.85 amid sharp annual decline - Investing.com India
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline By Investing.com - Investing.com South Africa
Adlai Nortye stock hits 52-week low at $1.85 amid sharp decline - Investing.com India
Adlai Nortye Announces Change in Auditing Firm - TipRanks
Adlai Nortye stock strengthened by oncology trial results, H.C. Wainwright keeps at Buy list - Investing.com India
Adlai Nortye IPO gives old Novartis cancer drug new life - BioPharma Dive
Adlai Nortye Announces 2.5M ADS IPO at $23/sh - Investing.com
CRVO Stock Quote Price and Forecast - CNN
Finanzdaten der Adlai Nortye Ltd Adr-Aktie (ANL)
Es liegen keine Finanzdaten für Adlai Nortye Ltd Adr (ANL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):